Sisram Medical Ltd. (HKG: 1696) announced that the registration application for the facial indication of Profhilo, its high‑concentration sodium hyaluronate injectable, was formally accepted in September 2026 by China’s National Medical Products Administration (NMPA) — a key procedural milestone that clears the product for substantive technical review in one of the world’s largest medical aesthetics markets.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Filing Type | Registration application – formal acceptance |
| Product | Profhilo (high‑concentration sodium hyaluronate injectable) |
| Indication | Facial application – skin texture, firmness and elasticity improvement |
| Acceptance Date | September 2026 (announced 20 Oct 2026) |
| Next Steps | Technical and clinical review by NMPA; injectable hyaluronic acid products are regulated in China as Class III medical devices – approval timeline not disclosed |
Product Profile & Mechanism of Action
- Composition: High‑concentration sodium hyaluronate (hyaluronic acid) formulation for intradermal injection.
- Proprietary Technology: Built on the patented NAHYCO (Natural Hybrid Cooperative) technology, an innovative manufacturing approach that stabilizes hyaluronic acid without chemical cross‑linking agents.
- BDDE‑Free Differentiation: The formulation contains no BDDE (1,4‑butanediol diglycidyl ether), the chemical cross‑linker used in most conventional dermal fillers — addressing a growing consumer and clinician preference for cleaner-label injectables.
- Mechanism: Works through dual bio‑stimulation and deep skin hydration pathways, designed to promote collagen and elastin regeneration rather than merely adding volume.
- Intended Aesthetic Effect: Improvement of skin texture and enhancement of skin firmness and elasticity — positioning Profhilo in the skin‑boosting / bio‑remodeling category rather than traditional volumizing fillers.
- Commercial Track Record: Already commercialized in multiple international markets; Sisram holds exclusive distribution rights for Profhilo in regions including Israel, India and Thailand.
Market Impact & Outlook
- China Aesthetics Landscape: Minimally invasive injectable procedures continue to outpace surgical options in China, and the bio‑stimulator / skin‑booster segment is among the fastest‑evolving categories — giving Profhilo a demand backdrop that favors differentiated, BDDE‑free formulations.
- Regulatory Positioning: Formal acceptance by the NMPA signals a complete and compliant dossier; the product now enters technical review, with any eventual approval required before commercial launch in China. Timing and outcome remain subject to regulatory review.
- Portfolio Expansion: A successful China registration would extend Sisram Medical’s footprint beyond its established energy‑based device portfolio into the high‑margin injectables segment, diversifying revenue across the aesthetics value chain.
- Distribution Footprint: Sisram’s existing exclusive rights across Israel, India and Thailand provide a proven commercialization playbook that can be adapted for the Chinese market, subject to local regulatory approval and partnership structure.
- Competitive Edge: Profhilo’s high‑concentration, non‑cross‑linked NAHYCO profile distinguishes it from conventional BDDE‑cross‑linked hyaluronic acid fillers, competing instead in the regenerative bio‑remodeling space where collagen and elastin regeneration — not volumization — is the primary value proposition.
- Disclosures: Clinical trial data, review timelines and commercial forecasts for the China market were not disclosed in the announcement.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the regulatory review timeline, potential approval, and commercial expectations for Profhilo in China. Actual results may differ materially due to risks including NMPA review outcomes, additional data requests, competitive dynamics in the Chinese aesthetics market, and distribution execution. Registration acceptance does not guarantee eventual marketing approval.-Fineline Info & Tech
